Targeting integrin pathways: mechanisms and advances in therapy
X Pang, X He, Z Qiu, H Zhang, R Xie, Z Liu… - … and Targeted Therapy, 2023 - nature.com
Integrins are considered the main cell-adhesion transmembrane receptors that play
multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in …
multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in …
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
One quarter of the global population is estimated to have nonalcoholic fatty liver disease
(NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by …
(NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by …
Non-alcoholic fatty liver disease: Definition and subtypes
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide, with a global prevalence of approximately 30%. However, the prevalence of …
worldwide, with a global prevalence of approximately 30%. However, the prevalence of …
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …
disease and affects nearly a quarter of the global population. The objective of this work was …
[HTML][HTML] Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis
Background & Aims Biopsy-confirmed liver fibrosis is a prognostic factor for patients with
nonalcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the …
nonalcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the …
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized public health
problem, affecting up to a quarter of the world's adult population. The burden of NAFLD is …
problem, affecting up to a quarter of the world's adult population. The burden of NAFLD is …
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
SA Harrison, VWS Wong, T Okanoue, N Bzowej… - Journal of …, 2020 - Elsevier
Background & Aims Apoptosis signal-regulating kinase 1 (ASK1) plays a key role in
hepatocyte injury, inflammation, and fibrosis in non-alcoholic steatohepatitis (NASH). We …
hepatocyte injury, inflammation, and fibrosis in non-alcoholic steatohepatitis (NASH). We …
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo …
C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan… - The lancet, 2019 - thelancet.com
Background Clinical decompensation of cirrhosis is associated with poor prognosis.
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …
[PDF][PDF] Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH)
are highly prevalent in the United States, where they are a growing cause of cirrhosis and …
are highly prevalent in the United States, where they are a growing cause of cirrhosis and …
[HTML][HTML] Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat
accumulation after the exclusion of other causes of hepatic steatosis, including other causes …
accumulation after the exclusion of other causes of hepatic steatosis, including other causes …